The collapse of adynomine production in 2011, and of US-based research and development during the ensuing civil war, dramatically spurred international research and development into alternative methods of chemical SLC-E negation. Zodytrin is to date the greatest success in that field, and the only product accepted for clinical use. Produced in the UK by Crito Sciences, a subsidiary of Crito Corporate, it was approved by the European Medicines Agency and entered the European market in 2014. It was additionally approved by the FDA in 2017, but the US market receives only limited quantities sold at elevated prices, greatly curtailing its availability.

Chemically related to phenylpropylaminopentane, zodytrin operates by a mechanism radically different from adynomine; rather than blocking the ADYR receptor, it causes monoaminergic synapses to release lower amounts of neurotransmitters, including those that propagate SLC-related neural signals. Injected into the bloodstream, the typical dosage takes effect within a minute and has an average duration of 11 hours, depending on the subject's metabolism. For long-term usage, zodytrin can be delivered by gel capsule, but must be taken twice daily and requires 2-3 weeks before its full effects are realized.

Because its mechanism is not SLC-E specific, zodytrin has a number of potential side effects, including: insomnia, drowsiness, headaches, blurred vision, agitation or nervousness, joint or muscle pain, upset stomach, nausea, diarrhea, and reduced sexual desire. Long-term usage of zodytrin has been implicated in risk for anxiety disorders, depression, migraines, and tremors; in particular, if tremors develop, they may persist after ceasing treatment. Thus, when using zodytrin for an extended period, it is important to tailor the dosage to the user to minimize side effects. Zodytrin may be contraindicated for those already at risk for depression, anxiety, and related psychiatric disorders; it can be used in combination with antidepressants to mitigate psychological effects.

For those using zodytrin over an extended period, its discontinuation also has side effects. When either stopping treatment after 1-3 weeks or tapering down the dosage to ease transition, discontinuation effects may include vivid dreams, poor sleep, dizziness, and irritability. Abrupt cessation after a month or more on the drug additionally causes powerful migraines, mood swings, and irregularly blunted SLC-E ability function. Discontinuation symptoms typically last 3–7 days after a dosage change, depending on the severity of reduction.


Zodytrin is available to licensed medical professionals and law enforcement institutions. Individual people looking to gain access to zodytrin must do so either through legitimate institutional channels or through black market connections. For legitimate channels, characters who are not licensed medical practitioners or within the listed factions must submit a +request. Black market characters looking to illegally sell zodytrin should also submit a +request.


Currently in the keeping of:
Government and medical institutions

Faction Access
Raytech SESA NYPD d'Sarthe Wolfhound Yamagato OEI Deveaux
Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License